Ellipses Pharma will develop GENA-104 (EP0089), a first-in-class monoclonal antibody targeting CNTN4, licensed from Genome & Company

GENA-104 acts on CNTN4, a newly discovered checkpoint protein, offering potential for patients unresponsive to current checkpoint inhibitors

A Phase 1 IND was approved in South Korea (Jan 2024), with trials expected to begin in 2025, expanding to the US and Europe later

Ellipses’ leadership highlights EP0089’s novel mechanism and potential impact on multiple cancer types